Great Novel Therapeutics Biotech & Medicals

NT$58.20As of Sun 8 Nov 2026, 12:00 UTC
TPEx:7427Healthcare
Country Taiwan
PE (Fwd) •••
TSR 5Y CAGR 12.69%
Div yield —
ROE (16.95%)
Biotechnology
Beta (5Y) 0.24
PE TTM —
TSR TTM 90.88%
Mkt cap NT$3.080B
ROIC (10.98%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
NT$61
4.21%
(47.63%)
Buy 8|3|8|6|6
4Q25
1Q26
2Q26
3Q26
Earnings per shareNT$
1.43
1.55
1.49
1.55
34.16%
31.15%
13.25%
15.12%
RevenueNT$M
142.4
144.9
143.5
142.1
1.71%
3.39%
5.52%
3.37%
Peers (US$92.70M)
Cap (US$)
PE
88.97M
—
92.95M
—
Capital
TTM
5Y
10Y
Leveragex
1.069
0.225
0.222
EBIT/Intx
0.141
0.441
0.411
Own earn%
65.83
38.47
21.41
Sh yield%
44.72
45.85
47.57
Owners
Insiders/Inst%
6.88
84.10
Short interest%
2.53
SBC / revenue%
5.69
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
4
Op margin range%
22–28
$1 testx
0.0
Incr. ROIC%
3